Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $65.00 at HC Wainwright

Pacira BioSciences (NASDAQ:PCRX - Free Report) had its price target hoisted by HC Wainwright from $48.00 to $65.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

PCRX has been the subject of several other reports. Needham & Company LLC upped their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $26.67.

Pacira BioSciences Stock Performance

Shares of PCRX traded up $0.87 during trading hours on Tuesday, hitting $24.56. The stock had a trading volume of 605,564 shares, compared to its average volume of 969,947. The firm has a 50-day moving average price of $24.74 and a 200 day moving average price of $20.81. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -12.10 and a beta of 0.71. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PCRX. State Street Corp boosted its holdings in shares of Pacira BioSciences by 5.8% in the third quarter. State Street Corp now owns 2,014,012 shares of the company's stock valued at $30,311,000 after acquiring an additional 110,162 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Pacira BioSciences by 0.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock worth $37,541,000 after purchasing an additional 13,604 shares in the last quarter. Geode Capital Management LLC increased its position in Pacira BioSciences by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after buying an additional 5,071 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Pacira BioSciences in the 4th quarter valued at about $20,266,000. Finally, Nuveen Asset Management LLC raised its position in shares of Pacira BioSciences by 109.9% in the fourth quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock valued at $11,792,000 after buying an additional 327,754 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.